Mauna Kea targets profitability by end-2027 after strong H1 sales growth

  • Mauna Kea reaffirmed its target to reach profitability by year-end 2027, citing a strengthened balance sheet and a solid H2 2026 system-sales pipeline.
  • H1 2026 sales rose to EUR 3.2 million from EUR 2.3 million, up 44% at constant exchange rates, led by Cellvizio adoption in U.S. pancreatic cysts.
  • Management forecast higher H2 2026 U.S. system sales, driven by pancreatic-cyst momentum, platform upgrade conversions, and seasonally stronger hospital capital spending.
  • CellTolerance growth remained a key expectation, with H1 sales of EUR 896,000 up 142% year over year, supported by rapid expansion in EMEA and ROW.
  • Liquidity runway was projected beyond 2027 including a new optional EUR 4 million shareholder-loan facility, supplementing EUR 5 million cash at end-2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260721192112) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.